President & CEO
Erica Rogers is the President and CEO of Silk Road Medical. Prior to Silk Road Medical, Erica was the COO of Medicines360, a non-profit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical, as well as the co-founder of Visiogen, which was acquired by Abbott Medical Optics in 2009. Erica spent over 12 years at Boston Scientific, in sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in zoology from San Diego State University. Erica holds five issued and 15 pending US patents in medical devices and nanotechnology.
Managing Director, Warburg Pincus
Elizabeth H. Weatherman joined Warburg Pincus in 1988 and leads the firm’s investment activities in the healthcare sector, an area in which she helped build the firm’s domain expertise. Ms. Weatherman is based in New York and is a director of ITC, JHP Pharmaceuticals, ReSearch Pharmaceutical Services, HD+, and Tornier. Ms. Weatherman received a B.A. summa cum laude in English from Mount Holyoke College and holds an MBA from the Stanford Graduate School of Business.
Principal, Warburg Pincus
Noah Knauf is based in San Francisco, joined Warburg Pincus in 2007 and focuses on investments in the Healthcare and Consumer group. Prior to joining Warburg Pincus, Mr. Knauf worked as an investment professional at Parthenon Capital and as a consultant at Bain & Company. He is a Director of Accriva Diagnostics, ComplexCare Solutions, Helix, Outset Medical, Silk Road Medical, Singular Bio, Sterigenics, and Vertice Pharma. Mr. Knauf received a B.S. summa cum laude in business administration from the University of Arizona and an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller scholar.
General Partner, The Vertical Group
Dr. Chou is a general partner at The Vertical Group, a healthcare focused venture capital firm. He co-founded Silk Road with Michi Garrison in 2007 and served as initial CEO. His career includes practicing as an interventional cardiologist and experience as a medical device industry executive. He previously had general management and business development responsibilities in the Abbott Vascular Division of Abbott Laboratories and last served as Division Vice President and General Manager of the vascular closure business managing the FDA approval and global launch of the Perclose Proglide and Starclose products. Prior to joining Abbott, Dr. Chou was the Director of the Adult Cardiac Catheterization Laboratory at the University of California, San Francisco where he remains Associate Professor of Medicine. Dr. Chou received an MD from Case Western Reserve University and a BS in Physics and Electrical Engineering from Carnegie Mellon University.
General Partner, The Vertical Group
Mr. Lasersohn has thirty years of experience in health care venture capital investments. Prior to joining The Vertical Group’s predecessor, F. Eberstadt in 1981 as a member of its venture capital division, Mr. Lasersohn was a corporate attorney with Cravath, Swaine & Moore. Mr. Lasersohn has served on the boards of over forty medical companies and currently serves on the Boards of Directors of Suture Concepts, Flexuspine, Masimo Corporation, Oncomed, Route 92 Medical, and Silk Road Medical. He previously served on the boards of Bacchus Vascular, CardioThoracic Systems, Inc., Cardiovascular Imaging Systems, Inc., E.P. Technologies, Integrated Vascular Systems, Kyphon Inc, Metabolix and Proteolix . Mr. Lasersohn served on the Executive Committee of the Board of Directors of the National Venture Capital Association and is a past Chairman of the Medical Industry Group of the NVCA . He was the recipient of the NVCA’s Outstanding Service Award in 2008. In 2011, Mr. Lasersohn served as an Entrepreneur in Residence at the FDA to develop an Innovation Pathway for medical devices. In 2012 he served as a panel member of the Medicare Coverage and Advisory Committee (MEDCAC). He received a B.S. degree in Physics from Tufts University, an M.A. from The Fletcher School of Law and Diplomacy, and a J.D. from Yale Law School.
Chairman of the Board, Principal, Walkabout Consulting LLC
Mr. Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm. Mr. Mott currently consults for Warburg Pincus as an Executive in Residence.
Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Mr. Mott held several executive positions, most recently as Chief Operating Officer at Wilson Greatbatch Technologies, Inc., a NYSE-listed medical technology company as well as executive operating roles within the Bristol-Myers Squibb Company.
Mr. Mott is currently Executive Chairman of the Board of Directors of Microchips Biotech, Inc., a company based on micro reservoir technology incorporating long-term implantable drug delivery technologies; Chairman of the Board of Directors of Silk Road Medical, a company which uses surgical techniques to protect the brain from stroke risk during carotid artery stenting; Executive Chairman of the Board of Directors of Relievant Medsystems, a company using therapeutic nerve ablation for the treatment of chronic low back pain; and member of the Board of Directors of Treace Medical Concepts, a company focused on foot and ankle surgical products.
Mr. Mott is a Director/Owner of VFD Technologies, a private equity firm that invests in, acquires and owns manufacturing businesses with unique technical capabilities that specialize in high performance materials.